FDA approves Ozurdex for treatment of certain patients with DME

The U.S. Food and Drug Administration has approved Ozurdex for the treatment of diabetic macular edema in certain patients, Allergan announced in a press release.The sustained-release, biodegradable dexamethasone intravitreal implant (Ozurdex, Allergan) 0.7 mg is indicated for adult patients with DME who have artificial lens implants or are scheduled for cataract surgery.

Full Story →